RosettaCommons/UTexasAptamer huggingface dataset:
Aptamer: Apt 8
Target: Eukaryotic translation initiation factor 4E (eIF4e)
Type of nucleic acid: ssDNA
Sequence: 5'ACACTCTTTCCCTACACGACGCTCTTCCGATCTTTGGTTGGAGGTGGTGGGGGGGGGGGGGGGGGAAGATCGGAAGAGCTC3'
Sequence length: 81
GC content: 0.6172839506172839
Affinity: Not reported
Pool type: 5′-ACACTCTTTCCCTACACGACGCTCTTCCGATCT-N33-AGATCGGAAGAGCTC-3′
Pool random region: 33
Binding buffer/conditions: Tris/Triton buffer (50 mmol/l Tris pH 8.0, 2 mmol/l EDTA, 100 mmol/l NaCL, 0.5% Triton X-100)
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: 25 kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " Development of DNA aptamer screens that are both simple and informative can increase the success rate of DNA aptamer selection and induce greater adoption. High eIF4e levels contribute to malignancies, thus eIF4e presents itself as a valuable target for DNA aptamer-based inhibition screen. Here, we demonstrate a method for the rapid selection of looped DNA aptamers against eIF4e. We show that ligation of looped aptamers can enhance their functional effects. These results demonstrate a rapid protocol to screen and optimize aptamers against macromolecules of interest."
Additional information: begins displacing the first class after round 7
Reference (2014, Mol Ther Nucleic Acids ): Guo, W. M., Kong, K. W., Brown, C. J., Quah, S. T., Yeo, H. L., Hoon, S., & Seow, Y. (2014). Identification and Characterization of an eIF4e DNA Aptamer That Inhibits Proliferation With High Throughput Sequencing. Molecular therapy. Nucleic acids, 3(12), e217. https://doi.org/10.1038/mtna.2014.70
Aptamer: Apt 9
Target: Eukaryotic translation initiation factor 4E (eIF4e)
Type of nucleic acid: ssDNA
Sequence: 5'ACACTCTTTCCCTACACGACGCTCTTCCGATCTGAGGGTGGTAAGTGTCTAAAGCCAGTTCTAGCGAGATCGGAAGAGCTC3'
Sequence length: 81
GC content: 0.5185185185185185
Affinity: Not reported
Pool type: 5′-ACACTCTTTCCCTACACGACGCTCTTCCGATCT-N33-AGATCGGAAGAGCTC-3′
Pool random region: 33
Binding buffer/conditions: Tris/Triton buffer (50 mmol/l Tris pH 8.0, 2 mmol/l EDTA, 100 mmol/l NaCL, 0.5% Triton X-100)
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: 25 kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " Development of DNA aptamer screens that are both simple and informative can increase the success rate of DNA aptamer selection and induce greater adoption. High eIF4e levels contribute to malignancies, thus eIF4e presents itself as a valuable target for DNA aptamer-based inhibition screen. Here, we demonstrate a method for the rapid selection of looped DNA aptamers against eIF4e. We show that ligation of looped aptamers can enhance their functional effects. These results demonstrate a rapid protocol to screen and optimize aptamers against macromolecules of interest."
Additional information: dominates early on in selection, peaking at rounds 3–6
Reference (2014, Mol Ther Nucleic Acids ): Guo, W. M., Kong, K. W., Brown, C. J., Quah, S. T., Yeo, H. L., Hoon, S., & Seow, Y. (2014). Identification and Characterization of an eIF4e DNA Aptamer That Inhibits Proliferation With High Throughput Sequencing. Molecular therapy. Nucleic acids, 3(12), e217. https://doi.org/10.1038/mtna.2014.70
Aptamer: Apt 10
Target: Eukaryotic translation initiation factor 4E (eIF4e)
Type of nucleic acid: ssDNA
Sequence: 5'ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTAGTTGCAGCTATACAACGTAACGTTATGTGAGATCGGAAGAGCTC3'
Sequence length: 81
GC content: 0.4814814814814814
Affinity: Not reported
Pool type: 5′-ACACTCTTTCCCTACACGACGCTCTTCCGATCT-N33-AGATCGGAAGAGCTC-3′
Pool random region: 33
Binding buffer/conditions: Tris/Triton buffer (50 mmol/l Tris pH 8.0, 2 mmol/l EDTA, 100 mmol/l NaCL, 0.5% Triton X-100)
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: 25 kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " Development of DNA aptamer screens that are both simple and informative can increase the success rate of DNA aptamer selection and induce greater adoption. High eIF4e levels contribute to malignancies, thus eIF4e presents itself as a valuable target for DNA aptamer-based inhibition screen. Here, we demonstrate a method for the rapid selection of looped DNA aptamers against eIF4e. We show that ligation of looped aptamers can enhance their functional effects. These results demonstrate a rapid protocol to screen and optimize aptamers against macromolecules of interest."
Additional information: dominates early on in selection, peaking at rounds 3–6
Reference (2014, Mol Ther Nucleic Acids ): Guo, W. M., Kong, K. W., Brown, C. J., Quah, S. T., Yeo, H. L., Hoon, S., & Seow, Y. (2014). Identification and Characterization of an eIF4e DNA Aptamer That Inhibits Proliferation With High Throughput Sequencing. Molecular therapy. Nucleic acids, 3(12), e217. https://doi.org/10.1038/mtna.2014.70
Aptamer: Apt 11
Target: Eukaryotic translation initiation factor 4E (eIF4e)
Type of nucleic acid: ssDNA
Sequence: 5'ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTTAGGCTGGGATGTCTGGGCTTCGCGGCAGTAAGATCGGAAGAGCTC3'
Sequence length: 81
GC content: 0.5555555555555556
Affinity: Not reported
Pool type: 5′-ACACTCTTTCCCTACACGACGCTCTTCCGATCT-N33-AGATCGGAAGAGCTC-3′
Pool random region: 33
Binding buffer/conditions: Tris/Triton buffer (50 mmol/l Tris pH 8.0, 2 mmol/l EDTA, 100 mmol/l NaCL, 0.5% Triton X-100)
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: 25 kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " Development of DNA aptamer screens that are both simple and informative can increase the success rate of DNA aptamer selection and induce greater adoption. High eIF4e levels contribute to malignancies, thus eIF4e presents itself as a valuable target for DNA aptamer-based inhibition screen. Here, we demonstrate a method for the rapid selection of looped DNA aptamers against eIF4e. We show that ligation of looped aptamers can enhance their functional effects. These results demonstrate a rapid protocol to screen and optimize aptamers against macromolecules of interest."
Additional information: begins displacing the first class after round 7
Reference (2014, Mol Ther Nucleic Acids ): Guo, W. M., Kong, K. W., Brown, C. J., Quah, S. T., Yeo, H. L., Hoon, S., & Seow, Y. (2014). Identification and Characterization of an eIF4e DNA Aptamer That Inhibits Proliferation With High Throughput Sequencing. Molecular therapy. Nucleic acids, 3(12), e217. https://doi.org/10.1038/mtna.2014.70
Aptamer: Apt 12
Target: Eukaryotic translation initiation factor 4E (eIF4e)
Type of nucleic acid: ssDNA
Sequence: 5'ACACTCTTTCCCTACACGACGCTCTTCCGATCTGATGTACAACCTTTTTTACCGAGAACACGGTGGAGATCGGAAGAGCTC3'
Sequence length: 81
GC content: 0.4938271604938271
Affinity: Not reported
Pool type: 5′-ACACTCTTTCCCTACACGACGCTCTTCCGATCT-N33-AGATCGGAAGAGCTC-3′
Pool random region: 33
Binding buffer/conditions: Tris/Triton buffer (50 mmol/l Tris pH 8.0, 2 mmol/l EDTA, 100 mmol/l NaCL, 0.5% Triton X-100)
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: 25 kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " Development of DNA aptamer screens that are both simple and informative can increase the success rate of DNA aptamer selection and induce greater adoption. High eIF4e levels contribute to malignancies, thus eIF4e presents itself as a valuable target for DNA aptamer-based inhibition screen. Here, we demonstrate a method for the rapid selection of looped DNA aptamers against eIF4e. We show that ligation of looped aptamers can enhance their functional effects. These results demonstrate a rapid protocol to screen and optimize aptamers against macromolecules of interest."
Additional information: dominates early on in selection, peaking at rounds 3–6
Reference (2014, Mol Ther Nucleic Acids ): Guo, W. M., Kong, K. W., Brown, C. J., Quah, S. T., Yeo, H. L., Hoon, S., & Seow, Y. (2014). Identification and Characterization of an eIF4e DNA Aptamer That Inhibits Proliferation With High Throughput Sequencing. Molecular therapy. Nucleic acids, 3(12), e217. https://doi.org/10.1038/mtna.2014.70
Aptamer: AptER-1
Target: Estrogen receptor alpha (ERα)
Type of nucleic acid: ssRNA
Sequence: 5’GGGCAGAGGCACCGCGAACAAAACGCAAGACAGAGUGCCGACAAGAGCACUACAAGCUUCUGCCC3'
Sequence length: 65
GC content: 0.5846153846153846
Affinity: Kd:16 nM
Pool type: 5'- GGGAGAAUUCAACUGCCAUCUAGGC-N50-AGUACUACAAGCUUCUGGACUCGGU-3'
Pool random region: 50
Binding buffer/conditions: Binding Buffer (1xBB): 12mM HEPES/pH 7.6, 150mM NaCl, and 10mM MgCl2
Divalent salt: MgCl
Buffer type: Other Buffers
pH: 7.6
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic and Drug Delivery: " Estrogen receptor α (ERα) is a well-validated drug target for a majority of breast cancers. But the target sites on this receptor are far from exhaustively defined. In this report, we describe the utility of RNA aptamers in the search for new drug target sites on ERα. Serving as a novel drug lead, it may also be used to guide the rational chemical synthesis of small molecule drugs or to perform screens of small molecule libraries for those that are able to displace the aptamer from its binding site."
Reference (2014, Nucleic Acid Ther ): Xu, D., Chatakonda, V. K., Kourtidis, A., Conklin, D. S., & Shi, H. (2014). In search of novel drug target sites on estrogen receptors using RNA aptamers. Nucleic acid therapeutics, 24(3), 226–238. https://doi.org/10.1089/nat.2013.0474
Aptamer: AptER-2
Target: Estrogen receptor alpha (ERα)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGAAUUCAACUGCCAUCUAGGCACACGCGAGAUAGAGCGAGGCCUCCAAAAAUGGCCACGCCAGGAAGCAGUACUACAAGCUUCUGGACUCGGU3'
Sequence length: 97
GC content: 0.5463917525773195
Affinity: Kd: 21 nM
Pool type: 5'- GGGAGAAUUCAACUGCCAUCUAGGC-N50-AGUACUACAAGCUUCUGGACUCGGU-3'
Pool random region: 50
Binding buffer/conditions: Binding Buffer (1xBB): 12mM HEPES/pH 7.6, 150mM NaCl, and 10mM MgCl3
Divalent salt: MgCl
Buffer type: Other Buffers
pH: 7.6
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic and Drug Delivery: " Estrogen receptor α (ERα) is a well-validated drug target for a majority of breast cancers. But the target sites on this receptor are far from exhaustively defined. In this report, we describe the utility of RNA aptamers in the search for new drug target sites on ERα. Serving as a novel drug lead, it may also be used to guide the rational chemical synthesis of small molecule drugs or to perform screens of small molecule libraries for those that are able to displace the aptamer from its binding site."
Reference (2014, Nucleic Acid Ther ): Xu, D., Chatakonda, V. K., Kourtidis, A., Conklin, D. S., & Shi, H. (2014). In search of novel drug target sites on estrogen receptors using RNA aptamers. Nucleic acid therapeutics, 24(3), 226–238. https://doi.org/10.1089/nat.2013.0474
Aptamer: AptER-3
Target: Estrogen receptor alpha (ERα)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGAAUUCAACUGCCAUCUAGGCGACCCAGGGCCGGGACGCAAAGCAGCCAAAACAGACGGCCCCAGUCAGGGAGUUACUACAAGCUUCUGGACUCGGU3'
Sequence length: 101
GC content: 0.5841584158415841
Affinity: Kd: 30 nM
Pool type: 5'- GGGAGAAUUCAACUGCCAUCUAGGC-N50-AGUACUACAAGCUUCUGGACUCGGU-3'
Pool random region: 50
Binding buffer/conditions: Binding Buffer (1xBB): 12mM HEPES/pH 7.6, 150mM NaCl, and 10mM MgCl4
Divalent salt: MgCl
Buffer type: Other Buffers
pH: 7.6
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic and Drug Delivery: " Estrogen receptor α (ERα) is a well-validated drug target for a majority of breast cancers. But the target sites on this receptor are far from exhaustively defined. In this report, we describe the utility of RNA aptamers in the search for new drug target sites on ERα. Serving as a novel drug lead, it may also be used to guide the rational chemical synthesis of small molecule drugs or to perform screens of small molecule libraries for those that are able to displace the aptamer from its binding site."
Reference (2014, Nucleic Acid Ther ): Xu, D., Chatakonda, V. K., Kourtidis, A., Conklin, D. S., & Shi, H. (2014). In search of novel drug target sites on estrogen receptors using RNA aptamers. Nucleic acid therapeutics, 24(3), 226–238. https://doi.org/10.1089/nat.2013.0474
Aptamer: CYN4
Target: Cytotoxin CNY
Type of nucleic acid: ssDNA
Sequence: 5′ATACCAGCTTATTCAATTGGCCACAACCCAACGACACTGACTGTACTGAATAATGTCTGTCAAACATCCGCGTGGTGAGATAGTAAGTGCAATCT3'
Sequence length: 95
GC content: 0.431578947368421
Affinity: Kd: 180.4 nM
Pool type: 5′-ATACCAGCTTATTCAATT-N60-AGATAGTAAGTGCAATCT-3
Pool random region: 60
Binding buffer/conditions: 50 mM Tris, pH 7.5, 150 mM NaCl, 2 mM MgCl2
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported 
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Biosensor: " Contamination of freshwater with cyanotoxin cylindrospermopsin (CYN) represents a significant global concern for public health. The sensitive detection of CYN is necessary to effectively manage and control the treatment of water resources. Here we report a novel, highly sensitive label-free aptasensor for CYN analysis, using aptamers as specific receptors. the aptasensor showed high specificity toward other coexistent cyanobacterial toxins of microcystin-LR and Anatoxin-a. Further biosensor designs will be generated using those aptamers for simple and sensitive CYN monitoring"
Additional information: Not applicable
Reference (2014, Anal Chem ): Elshafey, R., Siaj, M., & Zourob, M. (2014). In vitro selection, characterization, and biosensing application of high-affinity cylindrospermopsin-targeting aptamers. Analytical chemistry, 86(18), 9196–9203. https://doi.org/10.1021/ac502157g
Aptamer: CYN9
Target: Cytotoxin CNY
Type of nucleic acid: ssDNA
Sequence: 5′ATACCAGCTTATTCAATTGGCATCAGGCAACAACCGATGGTCCGGCCACCCTAACAACCAGCCCACCCACCACCCCGCCGAGATAGTAAGTGCAATCT3'
Sequence length: 98
GC content: 0.5408163265306123
Affinity: Kd: 88.78 nM
Pool type: 5′-ATACCAGCTTATTCAATT-N60-AGATAGTAAGTGCAATCT-3
Pool random region: 60
Binding buffer/conditions: 50 mM Tris, pH 7.5, 150 mM NaCl, 2 mM MgCl2
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported 
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Biosensor: " Contamination of freshwater with cyanotoxin cylindrospermopsin (CYN) represents a significant global concern for public health. The sensitive detection of CYN is necessary to effectively manage and control the treatment of water resources. Here we report a novel, highly sensitive label-free aptasensor for CYN analysis, using aptamers as specific receptors. the aptasensor showed high specificity toward other coexistent cyanobacterial toxins of microcystin-LR and Anatoxin-a. Further biosensor designs will be generated using those aptamers for simple and sensitive CYN monitoring"
Additional information: Not applicable
Reference (2014, Anal Chem ): Elshafey, R., Siaj, M., & Zourob, M. (2014). In vitro selection, characterization, and biosensing application of high-affinity cylindrospermopsin-targeting aptamers. Analytical chemistry, 86(18), 9196–9203. https://doi.org/10.1021/ac502157g
Aptamer: CYN19
Target: Cytotoxin CNY
Type of nucleic acid: ssDNA
Sequence: 5′ATACCAGCTTATTCAATTCACAGCGTGACACGGCAACCCACCCACCAGCCCCGTCAACGACCTATACCTGTGCTGCGCAAGATAGTAAGTGCAATCT3'
Sequence length: 97
GC content: 0.5154639175257731
Affinity: Kd: 87.4 nM
Pool type: 5′-ATACCAGCTTATTCAATT-N60-AGATAGTAAGTGCAATCT-3
Pool random region: 60
Binding buffer/conditions: 50 mM Tris, pH 7.5, 150 mM NaCl, 2 mM MgCl2
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported 
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Biosensor: " Contamination of freshwater with cyanotoxin cylindrospermopsin (CYN) represents a significant global concern for public health. The sensitive detection of CYN is necessary to effectively manage and control the treatment of water resources. Here we report a novel, highly sensitive label-free aptasensor for CYN analysis, using aptamers as specific receptors. the aptasensor showed high specificity toward other coexistent cyanobacterial toxins of microcystin-LR and Anatoxin-a. Further biosensor designs will be generated using those aptamers for simple and sensitive CYN monitoring"
Additional information: Not applicable
Reference (2014, Anal Chem ): Elshafey, R., Siaj, M., & Zourob, M. (2014). In vitro selection, characterization, and biosensing application of high-affinity cylindrospermopsin-targeting aptamers. Analytical chemistry, 86(18), 9196–9203. https://doi.org/10.1021/ac502157g
Aptamer: CYN26
Target: Cytotoxin CNY
Type of nucleic acid: ssDNA
Sequence: 5′ATACCAGCTTATTCAATTCACCAACGGACATCAGTACCCACCCGCCAGCCCCAACATCATGCCCATTCTGCGTGTCGAGATAGTAAGTGCAATCT3'
Sequence length: 95
GC content: 0.4947368421052631
Affinity: Kd: 176.3 nM
Pool type: 5′-ATACCAGCTTATTCAATT-N60-AGATAGTAAGTGCAATCT-3
Pool random region: 60
Binding buffer/conditions: 50 mM Tris, pH 7.5, 150 mM NaCl, 2 mM MgCl2
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported 
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Biosensor: " Contamination of freshwater with cyanotoxin cylindrospermopsin (CYN) represents a significant global concern for public health. The sensitive detection of CYN is necessary to effectively manage and control the treatment of water resources. Here we report a novel, highly sensitive label-free aptasensor for CYN analysis, using aptamers as specific receptors. the aptasensor showed high specificity toward other coexistent cyanobacterial toxins of microcystin-LR and Anatoxin-a. Further biosensor designs will be generated using those aptamers for simple and sensitive CYN monitoring"
Additional information: Not applicable
Reference (2014, Anal Chem ): Elshafey, R., Siaj, M., & Zourob, M. (2014). In vitro selection, characterization, and biosensing application of high-affinity cylindrospermopsin-targeting aptamers. Analytical chemistry, 86(18), 9196–9203. https://doi.org/10.1021/ac502157g
Aptamer: Apt.No.28
Target: Hepatitis B virus (HBV) core protein (HBc)
Type of nucleic acid: ssDNA
Sequence: 5′ACGCTCGGATGCCACTACAGGGTGGGATTCTATTTTATTCTGATTCTCCGTTCACTTTGCCTCATGGACGTGCTGGTGAC3′
Sequence length: 80
GC content: 0.5
Affinity: Not reported
Pool type: 5′-ACGCTCGGATGCCACTA CAG-N40-CTCATGGACGTGCTGGTGAC-3′
Pool random region: 40
Binding buffer/conditions: 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0
Buffer type: PBS/phosphate buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Drug Delivery: " Hepatitis B virus (HBV)-related hepatitis is a major health concern worldwide. As current anti-HBV therapies are limited, it is essential to develop new strategies. In the present study, by systematic evolution of ligand by exponential enrichment (SELEX), aptamers were screened against the core protein of HBV (HBc) from a random ssDNA library. The results provided a new ideal targeting molecule and may facilitate the strategy for targeted therapy as well as drug development of HBV-related diseases."
Reference (2014,Int J Mol Med): Zhang, Z., Zhang, J., Pei, X., Zhang, Q., Lu, B., Zhang, X., & Liu, J. (2014). An aptamer targets HBV core protein and suppresses HBV replication in HepG2.2.15 cells. International journal of molecular medicine, 34(5), 1423–1429. https://doi-org.ezproxy.lib.utexas.edu/10.3892/ijmm.2014.1908
Aptamer: Wy-5a
Target: Prostate cancer (PCa) cell line PC-3
Type of nucleic acid: ssDNA
Sequence: 5'ACGCTCGGATGCCACTACAGTGCCACTACAGCTGGTTCGGTTTGGTGACTTCGTTCTTCGTTGTGGTGCTTAGTGGCCTCATGGACGTGCTGGTGAC3′
Sequence length: 97
GC content: 0.5567010309278351
Affinity: Kd: 73.59±11.01 nM
Pool type: 5'-ACGCTCGGATGCCACTACAG-N45-CTCATGGACGTGCTGGTGAC-3′
Pool random region: 45
Binding buffer/conditions: Binding buffer was prepared by adding 1 mg/mL bovine serum albumin (BSA, Sigma) and 0.1 mg/mL Herring Sperm DNA (Invitrogen) to washing buffer (0.01 M PBS (contain 8 g NaCl, 0.2 g KCl, 3.58 g Na2HPO4·12H2O, 0.272 g KH2PO4 per 1 L ddH2O. pH = 7.4)
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " Morbidity and mortality of prostate cancer (PCa) have increased in recent years worldwide. Currently existing methods for diagnosis and treatment do not make the situation improve, especially for hormone refractory prostate cancer (HRPC). In this work, we have developed a new aptamer probe Wy-5a against PCa cell line PC-3 by cell-SELEX technique. The high affinity and specificity of Wy-5a makes this aptamer hold potential for application in diagnosis and target therapy of PCa."
Reference (2014, PLoS One ): Wang, Y., Luo, Y., Bing, T., Chen, Z., Lu, M., Zhang, N., Shangguan, D., & Gao, X. (2014). DNA aptamer evolved by cell-SELEX for recognition of prostate cancer. PloS one, 9(6), e100243. https://doi.org/10.1371/journal.pone.0100243
Aptamer: Wy-5b
Target: Prostate cancer (PCa) cell line PC-4
Type of nucleic acid: ssDNA
Sequence: 5'ACGCTCGGATGCCACTACAGTGCCACTAAGCTGGTTCGGTTTGGTGACTTCGTTCTTCGTTGTGGTGCTTAGTGGCCTCATGGACGTGCTGGTGAC3′
Sequence length: 96
GC content: 0.5520833333333334
Affinity: Kd: 173.1±44.67 nM
Pool type: 5'-ACGCTCGGATGCCACTACAG-N45-CTCATGGACGTGCTGGTGAC-3′
Pool random region: 45
Binding buffer/conditions: Binding buffer was prepared by adding 1 mg/mL bovine serum albumin (BSA, Sigma) and 0.1 mg/mL Herring Sperm DNA (Invitrogen) to washing buffer (0.01 M PBS (contain 8 g NaCl, 0.2 g KCl, 3.58 g Na2HPO4·12H2O, 0.272 g KH2PO4 per 1 L ddH2O. pH = 7.4)
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " Morbidity and mortality of prostate cancer (PCa) have increased in recent years worldwide. Currently existing methods for diagnosis and treatment do not make the situation improve, especially for hormone refractory prostate cancer (HRPC). In this work, we have developed a new aptamer probe Wy-5a against PCa cell line PC-3 by cell-SELEX technique. The high affinity and specificity of Wy-5a makes this aptamer hold potential for application in diagnosis and target therapy of PCa."
Reference (2014, PLoS One ): Wang, Y., Luo, Y., Bing, T., Chen, Z., Lu, M., Zhang, N., Shangguan, D., & Gao, X. (2014). DNA aptamer evolved by cell-SELEX for recognition of prostate cancer. PloS one, 9(6), e100243. https://doi.org/10.1371/journal.pone.0100243